LivaNova (NASDAQ:LIVN) Releases FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.200-4.300 for the period, compared to the consensus estimate of 4.100. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a report on Friday, January 9th. Piper Sandler reissued an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research note on Friday, March 27th. Needham & Company LLC boosted their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research note on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Trading Up 16.0%

LivaNova stock traded up $9.23 during mid-day trading on Wednesday, hitting $66.82. The company’s stock had a trading volume of 1,198,513 shares, compared to its average volume of 790,474. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -14.94 and a beta of 0.82. The business has a 50 day moving average price of $64.01 and a 200-day moving average price of $61.94. LivaNova has a 12 month low of $39.36 and a 12 month high of $71.92.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.30 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts forecast that LivaNova will post 3.66 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. Wellington Management Group LLP raised its stake in shares of LivaNova by 83.5% during the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the last quarter. Invesco Ltd. raised its stake in shares of LivaNova by 714.7% during the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after acquiring an additional 902,447 shares during the last quarter. Scopia Capital Management LP bought a new position in shares of LivaNova during the second quarter valued at about $36,657,000. Millennium Management LLC raised its stake in shares of LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after acquiring an additional 544,033 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after acquiring an additional 496,165 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.